Cardiovascular Health

Natural Heart & Cardiovascular Anti-Aging.

Healthy cardiovascular functioning is essential for maintaining a high quality of life, self-sufficiency, and longevity. The aging of the cardiovascular system is one of the most common diseases in modern society, with many factors contributing to cardiovascular decline, atherosclerosis and other cardiovascular problems. 


Vascular Strength™  is a powerful dietary cardiovascular supplement, which supports healthy cardiovascular functioning, and targets critical risk factors involved in  cardiovascular aging and associated disease development. Research indicates that the ingredients in Vascular Strength™ may support the health of the following cardiovascular areas:  


HDL facilitates the remove of cholesterol from the arteries and helps prevent the formation of atherosclerotic plaques. Paraoxonase-1, is an important enzyme which is closely associated with the functioning of HDL. Even with low levels of LDL, there is a significantly increased risk of heart disease when HDL levels are inadequate.

C-Reactive Protein is a an important indicator of the amount of inflammation occurring in the cardiovascular system. Recent research now indicates that inflammation is a major factor in the formation and progression of coronary plaques.Inflammation is also a known factor in reducing levels of HDL.

Dysfunction of the endothelium affects the ability of the artery to relax and dilate. The inability of the endothelium to function contributes to atherosclerosis development.

Elevated levels of LDL, triglycerides and glucose contribute to a higher risk of cardiovascular disease, including damage to the arteries.

The heart and myocardial cells are continuously exposed to many potentially damaging effects from oxidative stress, inflammation and other environmental factors.

  1. Munk PS, et al. Inflammation and C-reactive protein in cardiovascular disease. Tidsskr Nor Laegeforen. 2009 Jun 11;129(12):1221-4.
  2. Bispendial RJ, et al. C-reactive protein elicits white blood cell activation in humans. Am J Med. 2009 Jun;122(6):582.e1-9.
  3. Antony, B. et al. A Pilot Clinical Study to Evaluate the effect of Emblica Officialis Extract (AmlaMaxTM) on Markers of Systemic Inflammation and Dyslipidia. Indian Journal of Clinical Biochemistry, 2008 / 23 (4) 378-381
  4. Yokozawa T, et al. Amla (Emblica officinalis Gaertn.) prevents dyslipidaemia and oxidative stress in the ageing process. Br J Nutr. 2007 Jun;97(6):1187-95.
  5. Aggarwal BB, et al. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009 Feb;30(2):85-94.
  6. Almozning-Sarafian D, et al. Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration? Eur J Nutr. 2007 Jun;45(4):230-7
  7. King JL, et al. Inadequate dietary magnesium intake increases atherosclerotic plaque development in rabbits. Nutr Res. 2009 May;29(5):343-9
  8. Antony B, et al. A Pilot Clinical Study to Evaluate the Effect of Emblica Officinalis Extract (AmlaMax™) on Markers of Systemic Inflammation and Dyslipidemia. Indian Journal of Clinical Biochemistry, 2008 / 23 (4) 378-38
  9. Rajak S, et al. Emblica officinalis causes myocardial adaptation and protects against oxidative stress in ischemic reperfusion injury in rats. Phytother Res. 2004 Jan;18(1):54-6
  10. Kim HJ, et al. Influence of amla (Emblica officinalis Gaertn.) on hypercholesterolemia and lipid peroxidation in cholesterol-fed rats. J Nutr Sci Vitaminol (Tokyo). 2005 Dec;51(6):413-8
  11. Yokozawa T, et al. Amla (Emblica officinalis Gaertn.) prevents dyslipidaemia and oxidative stress in the aging process, Br J Nutr. 2007 Jun;97(6):1187-95
  12. Rao TP, et al. Amla (Embilca officinalis Gaertn.) extracts reduce oxidative stress in streptozotocin-induced diabetic rats. J Med Food. 2005 Fall;8(3):362-8
  13. Womgcharoen W, et al. The protective role of curcumin in cardiovascular diseases. Int J Cardiol. 2009 Apr 3;133(2):145-51
  14. Bengmark S. Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN J Parenter ENteral Nutr. 2006 Jan-Feb;30(1):45-51
  15. Oin L, et al. Effects and underlying mechanisms of curcumin on the proliferation of vascular smooth muscle cells induced by Chol:MbetaCD. Biochem Biophys Res Commun. 2009 Feb 6;379(2):277-82
  16. Antony B, et al. A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95® CG (BiocurcuminTM). A Novel Bioenhanced Preparation of Curcumin. Indian J. Pharm. Sci, 2008, 70(4)
  17. Gonzales AM, et al. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes, Nutr Metab (Lond). 2008 Jun 12;5:17.
  18. Menon VP, et al. Antioxidant and ant-inflammatory properties of curcumin. Adv Exp Med Biol. 2007;595:105-25.
  19. Jagetia GC, et al. “Spicing up” of the immune system by curcumin. J Clin Immunol. 2007 Jan;27(1):19-35
  20. Srivastava KC, et al. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot Essent Fatty Acids. 1995 Apr;52(4):223-7.
  21. Mahfouz MM, et al. Curcumin prevents the oxidation and lipid modification of LDL and its inhibition of prostacyclin generation by endothelial cells in culture. Prostaglandins Other Lipid Mediat. 2009 Jun 20.
  22. Samoamit K, et al. Curcumin improves vascular function and alleviates oxidative stress in non-lethal lipopolysaccharide-induced endotoxaemia in mice. Eur J Pharmacol. 2009 Jun 17
  23. Fang XD, et al. Curcumin ameliorates high glucose-induced vascular endothelial dysfunction in rat thoracic aorta. Clin Exp Pharmacol Physiol. 2009 May 19.
  24. Lara-Castro C, et al. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 2007 Jun;18(3):263-70.
  25. Kralisch S, et al. Adiokines in diabetes and cardiovascular diseases. Minerva Endocrinol. 2007 Sep;32(3):161-71.
  26. Ou XB, et al. Effects of curcumin on secretion of adiponectin and interleukin-6 in human adipose tissues: an in vitro study. Zhong Xi Yi Jie He Xue Bao. 2008 Jul;6(7):711-5.
  27. Marcu MG, et al. Curcumin is an inhibitor of p300 histone acetylatransferase. Med Chem. 2006 Mar;2(2):169-74.
  28. Morimoto T, et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest. 2008 Mar;118(3):868-78
  29. Feng B, et al. Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. Am J Physiol Endocrinol Metab. 2008 Jun;294(6):E1119-26.
  30. Hong D, et al. Altered profiles of gene expression in curcumin-treated rats with experimentally induced myocardial infarction. Pharmacol Res. 2009 Sep 9.
  31. Jang EM, et al. Beneficial effects of curcumin in hyperlipidemia and insulin resistance in high-fat-fed hamsters. Metabolism. 2008 Nov;57(11):1576-83.
  32. King DE. Inflammation and elevation of C-reactive protein: Does magnesium play a key role? Magnes Res. 2009 Jun;22(2):57-9.
  33. de Souza AW,et al. HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis. Autoimmune Rev. 2012 Oct;11(12):909-17.
  34. Kim DC, et al. Vascular anti-inflammatory effects of curcumin on HMGB1-mediated responses in vitro. Inflamm Res. 2011 Dec;60(12):1161-8